| Online-Ressource |
Verfasst von: | Kahn, Nicolas [VerfasserIn]  |
| Rossler, Anne-Kathrin [VerfasserIn]  |
| Hornemann, Katrin Emma [VerfasserIn]  |
| Muley, Thomas [VerfasserIn]  |
| Grünig, Ekkehard [VerfasserIn]  |
| Schmidt, Werner [VerfasserIn]  |
| Herth, Felix [VerfasserIn]  |
| Kreuter, Michael [VerfasserIn]  |
Titel: | C-proSP-B |
Titelzusatz: | a possible biomarker for pulmonary diseases? |
Verf.angabe: | Nicolas Kahn, Anne-Kathrin Rossler, Katrin Hornemann, Thomas Muley, Ekkehard Grünig, Werner Schmidt, Felix J.F. Herth, Michael Kreuter |
E-Jahr: | 2018 |
Jahr: | May 15,2018 |
Umfang: | 10 S. |
Teil: | volume:96 |
| year:2018 |
| number:2 |
| pages:117-126 |
| extent:10 |
Fussnoten: | Gesehen am 04.11.2019 |
Titel Quelle: | Enthalten in: Respiration |
Ort Quelle: | Basel : Karger, 1944 |
Jahr Quelle: | 2018 |
Band/Heft Quelle: | 96(2018), 2, Seite 117-126 |
ISSN Quelle: | 1423-0356 |
Abstract: | <b><i>Background:</i></b> Detection of surfactant proteins A and D (SP-A and SP-D) in the serum of patients with pulmonary diseases is thought to reflect an injury of the alveolar epithelial barrier and as such serve as a biomarker for these diseases. However, the data for SP-B are limited. <b><i>Objectives:</i></b> The aim of this feasibility study was to assess whether immature SP-B pre-proteins might have value as a possible biomarker for pulmonary diseases. <b><i>Methods:</i></b> In serum samples from patients with different chronic lung diseases (interstitial lung diseases [ILDs], chronic obstructive pulmonary disease, asthma, lung cancer, pulmonary hypertension, inflammation, patients on ventilator support; total <i>n</i> = 283), C-proSP-B was measured using an electrochemiluminescence immunoassay based on mouse monoclonal anti-C-proSP-B antibodies. Levels were correlated to lung functional and clinical parameters. <b><i>Results:</i></b> The highest C-proSP-B levels were detected in the serum of idiopathic pulmonary fibrosis (IPF) patients. In a multivariate analysis, C-proSP-B levels were able to discriminate IPF patients from patients with all other pulmonary diseases (<i>p</i> < 0.0001). No significant correlations were found between C-proSP-B levels and lung function, smoking history, or disease extent. <b><i>Conclusions:</i></b> SP-B pre-proteins might serve as a biomarker in pulmonary diseases with alveolar or interstitial damage such as ILDs, especially in IPF. Their role in the long-term monitoring of such diseases has to be clarified further. |
DOI: | doi:10.1159/000488245 |
URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: https://doi.org/10.1159/000488245 |
| Volltext: https://www.karger.com/Article/FullText/488245 |
| DOI: https://doi.org/10.1159/000488245 |
Datenträger: | Online-Ressource |
Sprache: | eng |
K10plus-PPN: | 1681064952 |
Verknüpfungen: | → Zeitschrift |